Finland · Delayed Price · Currency is EUR Herantis Pharma Oyj Earnings Call Transcripts
Fiscal Year 2026
-
HER-096 demonstrated clear biological activity in Parkinson's patients, with dose-dependent effects on proteostasis, mitochondrial function, and oxidative stress pathways. These biomarker findings support the drug's mechanism, reduce risk for Phase 2, and strengthen partnering prospects.
Fiscal Year 2025
-
HER-096 advanced through phase 1b with strong safety, brain penetration, and biomarker results, positioning for a phase two efficacy trial in Parkinson's disease. Financial position improved with grants and fundraising, but an additional EUR 20–25 million is needed to fully fund the next phase.
-
HER-096 phase I-B trial in Parkinson's patients met safety and PK endpoints, with most adverse events being mild injection site reactions and no drug-related serious events. PK data support twice-weekly dosing, and biomarker analysis is ongoing to inform phase II design and partnering.
-
HER-096, a potential first-in-class disease-modifying therapy for Parkinson's, advanced through phase I-B with top-line data expected by mid-October. Financials show increased R&D-driven loss and a strengthened cash position, but phase II requires new funding or partnerships.
Fiscal Year 2024
-
HER-096, a novel peptide for Parkinson's, showed strong safety and brain penetration in early trials, with phase 1b data expected in Q3 2025. Over EUR 6 million in non-dilutive funding was secured, and the cash runway extends into Q2 2026.
-
HER-096, a novel therapy for Parkinson's, is advancing through Phase Ib trials with strong preclinical and clinical safety data, targeting both symptomatic and disease-modifying effects. The program is well-funded, supported by major foundations, and is actively preparing for Phase II and partnering opportunities.
-
HER-096 shows strong preclinical and early clinical promise for Parkinson's, with robust funding and external validation supporting ongoing trials. Current cash will fund phase Ib, but more capital is needed for phase II. The market for disease-modifying therapies is expected to grow significantly.